Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New implant could help sleep apnea sufferers ditch the CPAP mask

NCT ID NCT03868618

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device that stimulates a nerve in the neck to keep the airway open during sleep. It is for adults with moderate to severe obstructive sleep apnea who cannot use a CPAP machine. The goal is to see if the device is safe and improves breathing and sleep quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 115 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age from 22 to 75 years (inclusive). Participant cannot be under guardianship, under curatorship or under judicial protection. 2. Body mass index (BMI) ≤ 32 kg/m2. 3. Cricomental space positive (≥ 0 cm). The cricomental space is the distance between the neck and the bisection of a line from the chin to the cricoid membrane when the head is in a neutral position. 4. Has either not tolerated, has failed or refused positive airway pressure (PAP) treatment 5. Moderate to severe OSA (15≤AHI4≤65 where combined central and mixed AHI \< 25% of the total AHI) based on a screening PSG. 6. Non-supine AHI \> 10 events on the screening PSG or participant has either not tolerated, has failed or refused positional therapy. 7. Written informed consent obtained from the participant prior to performing any study specific procedure. 8. Willing and capable to comply with all study requirements, including specific lifestyle considerations, performing all follow-up visits and sleep studies, evaluation procedures and questionnaires for the whole duration of the trial. 9. Willing to consent to long term follow-up of 5 years post-surgery. Exclusion Criteria: 1. Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment: 1. Severe chronic insomnia 2. Insufficient sleep syndrome (\<6 hours sleep per night) 3. Narcolepsy 4. Restless legs syndrome 5. REM behavior disorder 6. Others deemed sufficient disorders that would confound functional sleep assessment in the judgment of the investigator 2. Night shift worker defined as individual working between the hours of 10:00 pm and 7:00 am at least 3 nights per working week. 3. Taking medications that in the opinion of the investigator may alter consciousness, the pattern of respiration, or sleep architecture. 4. Major anatomical or functional abnormalities that would impair the ability of the Genio System to treat OSA: 1. Craniofacial abnormalities narrowing the airway or the implantation site 2. Palatine tonsil size 3+ or 4+ by the Brodsky Classification 3. Fixed upper airway obstructions (tumor, polyps, nasal obstruction) 4. Congenital malformations in the airway 5. Hypoglossal nerve palsy (bilateral limited tongue movement, or unilateral unintended tongue deviation during protrusion) 6. Existing swallowing difficulty as measured by a score of ≥3 on the EAT-10 questionnaire 7. Others deemed sufficient to impair the ability of the Genio® System to treat OSA in the judgment of the investigator 5. Significant comorbidities that contraindicate surgery or general anesthesia: 1. Revised Cardiac Risk Index Class III or IV 2. Persistent uncontrolled hypertension (defined as systolic pressure 160 mm Hg or a diastolic pressure of 120 mm Hg) despite medications 3. Coagulopathy or required anticoagulant medications (such as warfarin, clopidogrel (Plavix) or similar; prophylactic aspirin not exclusionary) that cannot be safely stopped in the perioperative period 4. Degenerative neurological disorder (i.e., Parkinson's disease, Alzheimer's disease) 5. Acute illness or infection 6. Diagnosed psychiatric disease (e.g., psychotic illness, uncontrolled major depression or acute anxiety attacks) that prevents participant compliance with the requirements of the investigational study testing 7. Substance or alcohol abuse history within the previous 3 years. Alcohol and substance abuse are defined as follows: i. Alcohol: no days with less than 3 or 4 standard drinks for women and men, respectively ii. Substance: the use of any substance in an amount unapproved by the investigator or considered illegal. The drugs most commonly abused include cocaine, marijuana, heroin (or substitution treatment), prescription drugs (especially painkillers), methamphetamines, and various other illegal substances. h) Life expectancy less than the primary endpoint study period (12 months post-surgery) i) Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia in the judgment of the investigator. 6. Prior surgery or treatments that could compromise the effectiveness of the Genio System: 1. Airway cancer surgery or radiation 2. Mandible or maxilla surgery in the previous 5 years (not counting dental treatments) 3. Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery) 4. Prior hypoglossal nerve stimulation device implantation 7. Has an Active Implantable Medical Device (AIMD) even if the device can be temporarily turned off. 8. Participation in another clinical study with an active treatment arm that could confound the results of the DREAM study. 9. Plan to become pregnant, currently pregnant, or breastfeeding during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Advanced Ear Nose & Throat Associates

    Atlanta, Georgia, 30342, United States

  • CENTA (Center for ENT & Allergy)

    Carmel, Indiana, 46032, United States

  • ENT and Allegy Associates South Florida

    Boca Raton, Florida, 33487, United States

  • Harvard/ Massachusetts Eye & Ear

    Boston, Massachusetts, 02114, United States

  • Hollywood Hospital

    Nedlands, Western Australia, 6005, Australia

  • Institute Breathing and Sleep Austin Hospital

    Heidelberg, Victoria, 3084, Australia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Ohio Sleep Medicine Institute

    Dublin, Ohio, 43017, United States

  • Technische Universität München

    München, 80333, Germany

  • The Ohio State University, Wexner Medical Center

    Columbus, Ohio, 43221, United States

  • The University of Tennessee Health Science Center- Dept. of Otolaryngology

    Memphis, Tennessee, 38163, United States

  • Thomas Jefferson University Department of Otolaryngology

    Philadelphia, Pennsylvania, 19107, United States

  • Universitair Ziekenhuis Antwerpen

    Antwerp, 2650, Belgium

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Iowa- Institute for Clinical & Translational Science

    Iowa City, Iowa, 52242, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 46032, United States

  • University of South Florida-Tampa General Medical Center

    Tampa, Florida, 33606, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

  • Weill Cornell Medicine Otolaryngology - Head and Neck Surgery

    New York, New York, 10024, United States

  • Wollongong Private Hospital

    Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.